Clinical bottom line
Hematopoietic stem cell transplantation (HSCT) remains a potentially curative option for selected patients with rare inherited bone marrow failure syndromes (IBMFS), including Fanconi anemia, dyskeratosis congenita, and Diamond-Blackfan anemia. Recent advances in conditioning regimens, donor selection, and supportive care have improved transplant outcomes, but significant risks of graft failure, transplant-related morbidity, and long-term complications persist. Careful patient selection, timing of transplantation, and genetic diagnosis are critical to optimize benefit-risk balance. HSCT should be considered in the context of multidisciplinary evaluation and evolving evidence, with individualized risk stratification guiding clinical decisions.
What the evidence shows
Inherited bone marrow failure syndromes are a heterogeneous group of rare disorders characterized by defective hematopoiesis and predisposition to malignancy. HSCT is currently the only curative therapy for hematologic manifestations in many IBMFS, but its application requires nuanced understanding of disease biology and transplant-specific risks.
Gluckman et al. (2007) provided early comprehensive data on HSCT outcomes in childhood IBMFS, highlighting improved survival with matched sibling donors and reduced-intensity conditioning regimens tailored to minimize toxicity in DNA repair-deficient disorders such as Fanconi anemia. More recent consensus statements and reviews (Darrigo Junior et al., 2020; 2021) emphasize advances in donor selection, including the use of unrelated and haploidentical donors, and the incorporation of next-generation sequencing for precise molecular diagnosis to guide transplant timing and conditioning intensity.
Narla Mohandas et al. (2018) summarized expert recommendations underscoring the importance of early HSCT before the onset of severe marrow failure or clonal evolution, particularly in Fanconi anemia and dyskeratosis congenita. They also noted that conditioning regimens must be carefully adapted to reduce DNA damage and organ toxicity, given the underlying genetic defects.
Loth et al. (2025) reported on recent improvements in transplant protocols, including the use of reduced-toxicity conditioning and enhanced graft-versus-host disease prophylaxis, which have contributed to better engraftment rates and survival outcomes. However, they caution that risks of late effects, such as secondary malignancies and organ dysfunction, remain substantial.
Dalle et al. (2016) reviewed allogeneic HSCT outcomes across IBMFS subtypes, confirming that transplant success varies by syndrome and patient-specific factors. They highlighted the need for ongoing surveillance post-transplant and the potential role of emerging therapies to complement or delay HSCT.
Finally, the impact of next-generation sequencing on transplant decision-making was explored by a recent pediatric study (2021), demonstrating that comprehensive genetic profiling can identify patients with non-DNA breakage defect IBMFS who may benefit from tailored transplant approaches or alternative therapies.
Caveats and uncertainty
Despite advances, HSCT in IBMFS carries significant risks, including graft failure, infections, graft-versus-host disease, and long-term sequelae such as secondary malignancies and organ toxicity. The rarity and heterogeneity of IBMFS limit large prospective trials, resulting in much evidence derived from retrospective cohorts and expert consensus, which may not fully capture patient diversity.
Optimal timing of HSCT remains debated, balancing the risks of progressive marrow failure and clonal evolution against transplant-related morbidity. Conditioning regimens require further refinement to minimize toxicity while ensuring engraftment, especially in DNA repair-deficient syndromes.
Genetic heterogeneity within IBMFS complicates risk stratification, and the long-term impact of HSCT on quality of life and non-hematologic manifestations is incompletely understood. Emerging therapies, including gene editing and novel pharmacologic agents, may alter future transplant indications but currently lack robust clinical data.
How this may change practice
Clinicians managing IBMFS should integrate comprehensive genetic diagnostics early to inform prognosis and transplant candidacy. Multidisciplinary evaluation involving hematologists, geneticists, and transplant specialists is essential to individualize HSCT timing and conditioning strategies.
Adoption of reduced-toxicity conditioning regimens and expanded donor options, including haploidentical transplantation, may increase transplant accessibility and improve outcomes. Long-term post-transplant surveillance protocols should be standardized to monitor for late complications.
Ongoing research into molecular pathogenesis and novel therapies may eventually shift the treatment paradigm, potentially delaying or obviating the need for HSCT in some cases. Meanwhile, clinicians should counsel patients and families on the benefits and risks of HSCT within the context of current evidence and evolving standards.